SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.

Winthrop, Kevin L; Whitley, Richard J; Aletaha, Daniel

Winthrop, Kevin L; Whitley, Richard J; Aletaha, Daniel.

Winthrop KL; Division of Infectious Diseases, and School of Public Health, Oregon Health & Science University, Portland, Oregon, USA winthrop@ohsu.edu.
Whitley RJ; Division of Infectious Diseases, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Aletaha D; Department of Rheumatology, Medical University of Vienna, Vienna, Austria.

Ann Rheum Dis ; 80(10): 1249-1251, 2021 10.

Article in English | MEDLINE | ID: covidwho-1406638

Subject(s)

COVID-19 Vaccines/therapeutic use; COVID-19/prevention & control; Immunocompromised Host/immunology; Rheumatic Diseases/complications; Rheumatic Diseases/immunology; COVID-19/complications; COVID-19 Vaccines/immunology; Humans; Immunization, Secondary; Rheumatology; SARS-CoV-2

Keywords

COVID-19; autoimmune diseases; vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / Immunocompromised Host / COVID-19 Vaccines / COVID-19 Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2021-221251

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google